{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:37:28Z","timestamp":1764859048948},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.mcna.2018.02.009","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T07:35:05Z","timestamp":1529393705000},"page":"667-681","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["When and How to Treat Possible Cannabis Use Disorder"],"prefix":"10.1016","volume":"102","author":[{"given":"Annie","family":"L\u00e9vesque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2018.02.009_bib1","unstructured":"United Nations Office on Drugs and Crime. World drug report 2016. Vienna (Austria): 2016. Available at: http:\/\/www.unodc.org\/wdr2016\/. Accessed June, 2017."},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1521-0391.2013.00321.x","article-title":"Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample","volume":"22","author":"Lev-Ran","year":"2013","journal-title":"Am J Addict"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2018.02.009_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugalcdep.2010.11.004","article-title":"Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)","volume":"115","author":"Lopez-Quintero","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.009_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aap.2014.12.015","article-title":"Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States","volume":"76","author":"Le Strat","year":"2015","journal-title":"Accid Anal Prev"},{"key":"10.1016\/j.mcna.2018.02.009_bib5","unstructured":"SAMHSA. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health. 2017. Available at: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FFR1-2015\/NSDUH-FFR1-2015\/NSDUH-FFR1-2015.htm#sudyr04. Accessed June, 2017."},{"issue":"2","key":"10.1016\/j.mcna.2018.02.009_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1369-1600.2008.00108.x","article-title":"Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond","volume":"13","author":"Pertwee","year":"2008","journal-title":"Addict Biol"},{"key":"10.1016\/j.mcna.2018.02.009_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu Rev Psychol"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.009_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/bjp.2008.130","article-title":"The endocannabinoid system in brain reward processes","volume":"154","author":"Solinas","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2018.02.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-3084(00)00184-5","article-title":"A\u00a0historical overview of chemical research on cannabinoids","volume":"108","author":"Mechoulam","year":"2000","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.mcna.2018.02.009_bib10","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.009_bib11","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S1516-4446(12)70057-0","article-title":"Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug","volume":"34","author":"Schier","year":"2012","journal-title":"Rev Bras Psiquiatr"},{"issue":"1607","key":"10.1016\/j.mcna.2018.02.009_bib12","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","article-title":"Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man","volume":"28","author":"Karniol","year":"1974","journal-title":"Eur J Pharmacol"},{"issue":"21","key":"10.1016\/j.mcna.2018.02.009_bib15","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2018.02.009_bib16","series-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","first-page":"486","year":"2017"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.009_bib17","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.mcna.2018.02.009_bib18","series-title":"Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5)","author":"American Psychiatric Association","year":"2013"},{"issue":"1\u20133","key":"10.1016\/j.mcna.2018.02.009_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2011.11.007","article-title":"Diagnostic criteria for cannabis withdrawal syndrome","volume":"123","author":"Gorelick","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"10.1016\/j.mcna.2018.02.009_bib20","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.addbeh.2008.02.001","article-title":"Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence","volume":"33","author":"Cornelius","year":"2008","journal-title":"Addict Behav"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.009_bib21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","article-title":"Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States","volume":"79","author":"ElSohly","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.009_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/jamapediatrics.2013.140","article-title":"Pediatric marijuana exposures in a medical marijuana state","volume":"167","author":"Wang","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.009_bib23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/acem.12655","article-title":"Cyclic vomiting presentations following marijuana liberalization in Colorado","volume":"22","author":"Kim","year":"2015","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.mcna.2018.02.009_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jhealeco.2015.03.007","article-title":"The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances","volume":"42","author":"Wen","year":"2015","journal-title":"J\u00a0Health Econ"},{"issue":"9","key":"10.1016\/j.mcna.2018.02.009_bib25","first-page":"801","article-title":"Approach to cannabis use disorder in primary care: focus on youth and other high-risk users","volume":"60","author":"Turner","year":"2014","journal-title":"Can Fam Physician"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.009_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2017.303818","article-title":"Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations","volume":"107","author":"Fischer","year":"2017","journal-title":"Am J Public Health"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.009_bib27","article-title":"Psychosocial interventions for cannabis use disorder","author":"Gates","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2018.02.009_bib28","series-title":"Cognitive therapy of substance abuse","author":"Beck","year":"1993"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.009_bib29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1037\/0022-006X.68.5.898","article-title":"Comparison of extended versus brief treatments for marijuana use","volume":"68","author":"Stephens","year":"2000","journal-title":"J\u00a0Consult Clin Psychol"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.009_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0740-5472(01)00179-9","article-title":"A\u00a0randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder","volume":"21","author":"Copeland","year":"2001","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.mcna.2018.02.009_bib31","series-title":"Motivational interviewing: preparing people for change","author":"Miller","year":"2002"},{"issue":"10","key":"10.1016\/j.mcna.2018.02.009_bib32","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/archpsyc.62.10.1148","article-title":"Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study","volume":"62","author":"Petry","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.009_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archpsyc.63.2.201","article-title":"Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study","volume":"63","author":"Peirce","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.009_bib34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.drugalcdep.2009.07.009","article-title":"A\u00a0randomized trial of contingency management for adolescent marijuana abuse and dependence","volume":"105","author":"Stanger","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.009_bib35","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ajp.2012.12010055","article-title":"A\u00a0double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents","volume":"169","author":"Gray","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.009_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","article-title":"A\u00a0randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults","volume":"177","author":"Gray","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drugalcdep.2006.04.014","article-title":"Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms","volume":"86","author":"Budney","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.npp.1300310","article-title":"Marijuana withdrawal in humans: effects of oral THC or divalproex","volume":"29","author":"Haney","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.mcna.2018.02.009_bib39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2018.02.009_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugalcdep.2012.08.001","article-title":"The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users","volume":"128","author":"Vandrey","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","article-title":"Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse","volume":"197","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.009_bib42","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/npp.2013.54","article-title":"Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse","volume":"38","author":"Haney","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.009_bib43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.009_bib44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","article-title":"Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings","volume":"161","author":"Trigo","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.009_bib45","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/npp.2012.14","article-title":"A\u00a0proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults","volume":"37","author":"Mason","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/00952990.2013.819362","article-title":"Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study","volume":"40","author":"Weinstein","year":"2014","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550490802408936","article-title":"A\u00a0preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence","volume":"18","author":"Carpenter","year":"2009","journal-title":"Am J Addict"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.009_bib48","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/add.12108","article-title":"A\u00a0randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders","volume":"108","author":"Levin","year":"2013","journal-title":"Addiction"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2018.02.009_bib49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drugalcdep.2010.05.010","article-title":"Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults","volume":"112","author":"Cornelius","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.009_bib50","first-page":"63","article-title":"Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study","volume":"6","author":"Penetar","year":"2012","journal-title":"Subst Abuse"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.009_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002130000657","article-title":"Bupropion SR worsens mood during marijuana withdrawal in humans","volume":"155","author":"Haney","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10550490490265280","article-title":"Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium","volume":"13","author":"Levin","year":"2004","journal-title":"Am J Addict"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2018.02.009_bib53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2009.06.022","article-title":"A\u00a0placebo-controlled trial of buspirone for the treatment of marijuana dependence","volume":"105","author":"McRae-Clark","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.009_bib54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1521-0391.2010.00076.x","article-title":"A\u00a0placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder","volume":"19","author":"McRae-Clark","year":"2010","journal-title":"Am J Addict"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.009_bib55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-010-1888-6","article-title":"Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse","volume":"211","author":"Haney","year":"2010","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pbb.2010.12.013","article-title":"The safety of modafinil in combination with oral 9-tetrahydrocannabinol in humans","volume":"98","author":"Sugarman","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00213-002-1279-8","article-title":"Interaction between naltrexone and oral THC in heavy marijuana smokers","volume":"166","author":"Haney","year":"2003","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.009_bib58","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1369-1600.2012.00461.x","article-title":"A\u00a0human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers","volume":"18","author":"Cooper","year":"2013","journal-title":"Addict Biol"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.009_bib59","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.009_bib60","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","article-title":"Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users","volume":"194","author":"Huestis","year":"2007","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.mcna.2018.02.009_bib61","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/npp.2016.27","article-title":"Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys","volume":"41","author":"Schindler","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"10.1016\/j.mcna.2018.02.009_bib62","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.009_bib63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2826.2008.01681.x","article-title":"CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant","volume":"20","author":"Scheen","year":"2008","journal-title":"J\u00a0Neuroendocrinol"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.009_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw068","article-title":"The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability","volume":"19","author":"Gueye","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.mcna.2018.02.009_bib65","series-title":"Understanding the \u2018spice\u2019 phenomenon","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2009"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.009_bib66","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pnpbp.2012.04.017","article-title":"Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids","volume":"39","author":"Seely","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.009_bib67","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2174\/0929867054020864","article-title":"Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes","volume":"12","author":"Huffman","year":"2005","journal-title":"Curr Med Chem"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.009_bib68","doi-asserted-by":"crossref","first-page":"e21917","DOI":"10.1371\/journal.pone.0021917","article-title":"Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in\u00a0vitro and in\u00a0vivo cannabinoid 1 receptor affinity and activity","volume":"6","author":"Brents","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.009_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A\u00a0systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"issue":"27","key":"10.1016\/j.mcna.2018.02.009_bib70","doi-asserted-by":"crossref","first-page":"692","DOI":"10.15585\/mmwr.mm6527a2","article-title":"Acute poisonings from synthetic cannabinoids - 50\u00a0U.S. toxicology investigators consortium registry sites, 2010-2015","volume":"65","author":"Riederer","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.009_bib71","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.annemergmed.2012.03.007","article-title":"A\u00a0characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010","volume":"60","author":"Hoyte","year":"2012","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.009_bib72","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11920-016-0694-1","article-title":"Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal","volume":"18","author":"Cooper","year":"2016","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.009_bib73","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings","volume":"108","author":"Hermanns-Clausen","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.009_bib74","first-page":"3","article-title":"A\u00a0gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid","volume":"2014","author":"Ukaigwe","year":"2014","journal-title":"Case Rep Emerg Med"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.009_bib75","first-page":"296","article-title":"The synthetic cannabinoid withdrawal syndrome","volume":"7","author":"Nacca","year":"2013","journal-title":"J\u00a0Addict Med"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.009_bib76","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dar.12225","article-title":"Synthetic cannabinoid withdrawal: a new demand on detoxification services","volume":"34","author":"Macfarlane","year":"2015","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.009_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2004.02.001","article-title":"Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment","volume":"74","author":"Hernandez-Avila","year":"2004","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"10.1016\/j.mcna.2018.02.009_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drugalcdep.2012.10.015","article-title":"Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions","volume":"130","author":"Khan","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.009_bib79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/00952990.2010.503825","article-title":"Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal","volume":"36","author":"Copersino","year":"2010","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.009_bib80","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1037\/pha0000053","article-title":"Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users","volume":"23","author":"Herrmann","year":"2015","journal-title":"Exp Clin Psychopharmacol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T19:06:00Z","timestamp":1534187160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712518300130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0025712518300130"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.009","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When and How to Treat Possible Cannabis Use Disorder","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}